The FDA confirmed its willingness to review NRx Pharmaceuticals’ application for New Drug Approval of NRX-100, a ketamine-based treatment for depression, based on substantial evidence of effectiveness from existing trials. Notably, the agency did not request additional clinical trials, and the company plans to submit its New Drug Application by June 2026 using existing patient-level data, which could expedite the approval process. NRX-100 has demonstrated dramatic superiority to placebo in reducing suicidal ideation and non-inferiority compared to electroconvulsive therapy (electroshock therapy), which is the only currently approved treatment for suicidal ideation.
Safety Profile and Clinical Benefits
Ketamine has demonstrated statistically significant reduction in suicidal ideation. In trials, electroshock therapy showed a 30% incidence of memory loss, whereas ketamine did not. This positions NRx Pharmaceuticals to potentially address a critical market need: over 16 million Americans experience depression annually, with 3.6 million contemplating suicide. The treatment approach is particularly significant given the lack of alternatives and the memory impairment risks associated with current approved therapies for suicidal ideation.
Stock Performance and Analyst Outlook
NRx Pharmaceuticals shares were up 11.70% at $2.07 at the time of publication on Monday. The stock carries a Buy Rating from multiple analysts, with D. Boral Capital maintaining a target of $34.00 as of March 9, HC Wainwright & Co. raising its target to $45.00 as of March 3, and BTIG maintaining a target of $25.00 as of February 18. Technically, the stock is trading 14.8% above its 20-day simple moving average and 3.3% above its 50-day SMA, indicating short-term strength, though it remains 8.2% below its 100-day SMA, suggesting challenges in maintaining longer-term momentum. The RSI is at 48.03, indicating neutral territory, while the MACD suggests a bullish crossover with the MACD above its signal line.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/news/fda/26/03/51277695/nrx-pharma-stock-jumps-after-fda-signals-path-to-nda-for-ketamine-depression-drug